Immunocore (IMCR) Stock Price, News & Analysis

Company Overview

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Key Stats

• Today's Range: $28.41 to $29.58
• 50-Day Range: $28.20 to $33.00
• 52-Week Range: $27.19 to $64.11
• Volume: 234,006 shs
• Average Volume: 441,598 shs
• Market Capitalization: $1.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.64
• Consensus Rating: Moderate Buy

Immunocore Stock Analysis - MarketRank™

Immunocore scored higher than 37% of companies evaluated by MarketBeat, and ranked 732nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immunocore has received a consensus rating of Moderate Buy. The company's average rating score is 2.54, and is based on 8 buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Immunocore has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Immunocore are expected to decrease in the coming year, from ($0.94) to ($1.62) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunocore is -30.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunocore is -30.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunocore has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.17% of the float of Immunocore has been sold short.

Short Interest Ratio / Days to Cover

Immunocore has a short interest ratio ("days to cover") of 26.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunocore has recently increased by 2.15%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunocore does not currently pay a dividend.

Dividend Growth

Immunocore does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.17% of the float of Immunocore has been sold short.

Short Interest Ratio / Days to Cover

Immunocore has a short interest ratio ("days to cover") of 26.6, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunocore has recently increased by 2.15%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.19

News Sentiment

Immunocore has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Immunocore this week, compared to 4 articles on an average week.

MarketBeat Follows

8 people have added Immunocore to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Immunocore insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,994,085.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 9.10% of the stock of Immunocore is held by insiders.

Percentage Held by Institutions

84.50% of the stock of Immunocore is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMCR Stock Analysis - Frequently Asked Questions

How have IMCR shares performed this year?

Immunocore's stock was trading at $29.50 on January 1st, 2025. Since then, IMCR stock has decreased by 1.6% and is now trading at $29.04.
View the best growth stocks for 2025 here.

How were Immunocore's earnings last quarter?

Immunocore Holdings plc (NASDAQ:IMCR) posted its quarterly earnings data on Wednesday, November, 6th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.50. Immunocore's quarterly revenue was up 23.7% on a year-over-year basis.

When did Immunocore IPO?

Immunocore (IMCR) raised $199 million in an initial public offering on Friday, February 5th 2021. The company issued 8,300,000 shares at $23.00-$25.00 per share. Goldman Sachs, J.P. Morgan and Jefferies served as the underwriters for the IPO.

How do I buy shares of Immunocore?

Shares of IMCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immunocore own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunocore investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/06/2024
• Today: 4/04/2025
• Next Earnings (Estimated): 5/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMCR
• CIK: 1671927
• Web: www.immunocore.com
• Phone: 44-12-3543-8600
• Fax: N/A
• Employees: 320
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $65.64
• High Stock Price Target: $100.00
• Low Stock Price Target: $24.00
• Potential Upside/Downside: +126.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.54
• Research Coverage: 13 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-55,290,000.00
• Net Margins: -15.87%
• Pretax Margin: -18.14%
• Return on Equity: -12.84%
• Return on Assets: -5.09%

Debt

• Debt-to-Equity Ratio: 1.03
• Current Ratio: 3.78
• Quick Ratio: 3.76

Sales & Book Value

• Annual Sales: $310.20 million
• Price / Sales: 4.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.42 per share
• Price / Book: 3.91

Miscellaneous

• Outstanding Shares: 50,033,000
• Free Float: 45,480,000
• Market Cap: $1.45 billion
• Optionable: Optionable
• Beta: 0.79